Accessibility Menu
 
Connect Biopharma logo

Connect Biopharma

(NASDAQ) CNTB

Current Price$2.78
Market Cap$154.29M
Since IPO (2025)+39%
5 Year-85%
1 Year+234%
1 Month-6%

Connect Biopharma Financials at a Glance

Market Cap

$154.29M

Revenue (TTM)

$26.08M

Net Income (TTM)

$57.39M

EPS (TTM)

$-0.28

P/E Ratio

-9.75

Dividend

$0.00

Beta (Volatility)

0.51 (Low)

Price

$2.78

Volume

112,541.985

Open

$2.79

Previous Close

$2.76

Daily Range

$2.69 - $2.88

52-Week Range

$0.51 - $3.28

CNTB News

No articles available.

CNTB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Connect Biopharma

Industry

Biotechnology

Employees

62

CEO

Barry D. Quart, PharmD

Headquarters

Taicang, 215400, CN

CNTB Financials

Key Financial Metrics (TTM)

Gross Margin

91%

Operating Margin

-20%

Net Income Margin

-18%

Return on Equity

0%

Return on Capital

-53%

Return on Assets

-44%

Earnings Yield

-10.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$154.29M

Shares Outstanding

55.90M

Volume

112.54K

Short Interest

0.00%

Avg. Volume

103.67K

Financials (TTM)

Gross Profit

$26.03M

Operating Income

$22.45M

EBITDA

$21.79M

Operating Cash Flow

$23.61M

Capital Expenditure

$750.00K

Free Cash Flow

$24.36M

Cash & ST Invst.

$93.71M

Total Debt

$178.00K

Connect Biopharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$48.00K

N/A

Gross Profit

$48.00K

+109.5%

Gross Margin

100.00%

N/A

Market Cap

$154.29M

N/A

Market Cap/Employee

$2.49M

N/A

Employees

62

N/A

Net Income

$12.90M

+57.8%

EBITDA

$13.25M

+55.8%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Net Cash

$70.90M

-45.7%

Accounts Receivable

$193.00K

+284.1%

Inventory

$0.00

-100.0%

Long Term Debt

$520.00K

+61.8%

Short Term Debt

$700.00K

+158.6%

Return on Assets

-43.66%

N/A

Return on Invested Capital

-53.25%

N/A

Free Cash Flow

$12.89M

+58.9%

Operating Cash Flow

$12.59M

+59.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STROSutro Biopharma, Inc.
$20.68-2.08%
ARTVArtiva Biotherapeutics, Inc.
$5.32-3.62%
KLRSKalaris Therapeutics Inc
$6.57-3.52%
OVIDOvid Therapeutics Inc.
$2.62+13.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
RITMRithm Capital
$8.77-0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%
ANNAAleAnna
$7.07+0.87%

Questions About CNTB

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.